Invention Application
- Patent Title: BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
-
Application No.: US18833267Application Date: 2023-01-27
-
Publication No.: US20250101102A1Publication Date: 2025-03-27
- Inventor: Christopher W. L. CHIU , Mariana C. STIRNER , Minh H. DINH , Iliana E. SZAFER-GLUSMAN
- Applicant: GENMAB A/S
- Applicant Address: DK Valby
- Assignee: GENMAB A/S
- Current Assignee: GENMAB A/S
- Current Assignee Address: DK Valby
- International Application: PCT/EP2023/052005 WO 20230127
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K31/573 ; A61K39/00 ; A61P35/00
Abstract:
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).
Information query
